• Explore /
  • Poster
  • / Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

Abstract Poster

Authors

Karina Steffensen

Karina Dahl Steffensen

Department of Clinical Oncology and Radiotherapy, Vejle Hospital, Vejle, Denmark

Karina Dahl Steffensen , Marianne Waldstrøm , Niels Pallisgaard , Bente Lund , Kjell Bergfeldt , Jessica Wihl , Nina Keldsen , Christian Marth , Ignace B. Vergote , Anders Kristian Moeller Jakobsen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT00861120

Citation

J Clin Oncol 30, 2012 (suppl; abstr 5052)

DOI

10.1200/jco.2012.30.15_suppl.5052

Abstract #

5052

Poster Bd #

19D

Abstract Disclosures

Similar Posters

First Author: Radoslav Chekerov

First Author: I. Chau

First Author: Samuel A. Jacobs

Poster

2016 Gastrointestinal Cancers Symposium

Perioperative chemotherapy using FOLFOX with panitumumab for locally advanced rectal cancer: Phase II trial.

Perioperative chemotherapy using FOLFOX with panitumumab for locally advanced rectal cancer: Phase II trial.

First Author: Mitsuyoshi Ota